{"classes":[{"categories":[{"measurements":[{"comment":"The median and upper limit of the 95% confidence interval were not calculable because an insufficient number of participants reached the event.","groupId":"OG000","lowerLimit":"12.91","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event.","groupId":"OG001","lowerLimit":"5.55","upperLimit":"NA","value":"5.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"The DOR is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.1 or to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to this arm received the study drug, tivozanib hydrochloride.","id":"OG000","title":"Tivozanib Hydrochloride"},{"description":"Participants randomized to this arm received the comparator drug, sorafenib.","id":"OG001","title":"Sorafenib"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Assessed every 8 weeks from date of randomization until date of progression (up to approximately 5 years)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}